Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
Executive Summary
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.